Safety and efficacy of recombinant factor VIIa by pediatric age cohort: reassessment of compassionate use and trial data supporting US label-Reference-Cited by-同舟云学术

Safety and efficacy of recombinant factor VIIa by pediatric age cohort: reassessment of compassionate use and trial data supporting US label

Author:

Croteau Stacy E.¹,Nakar Charles²,Neufeld Ellis J.¹,Shapiro Amy²,Cooper David L.³

Affiliation:

1. Dana‐Farber/Boston Children's Cancer & Blood Disorders Center, Boston Hemophilia Center Boston Children's Hospital Boston Massachusetts

2. Indiana Hemophilia and Thrombosis Center Indianapolis Indiana

3. Clinical, Medical and Regulatory Affairs Novo Nordisk Inc Plainsboro New Jersey

Funder

Novo Nordisk

Publisher

Wiley

Subject

Oncology,Hematology,Pediatrics, Perinatology, and Child Health

Link

Reference22 articles.

2. NovoSeven RT[package insert]. Bagsvaerd Denmark: NovoNordisk A/S; 2015.

5. Recombinant factor VIIa in joint and muscle bleeding episodes;Bech RM.;Haemostasis,1996

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献